FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for STRIBILD, a fixed-dose combination antiretroviral, to be produced by Gilead Sciences, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Cobicistat (cobicistat)
• Emtricitabine (Emtricitabine)
• Stribild (elvitegravir; cobicistat; emtricitabine; tenofovir disoproxil fumarate)
• TENOFOVIR DISOPROXIL FUMARATE (tenofovir disoproxil fumarate)
• elvitegravir (elvitegravir)

Snippet

SUPPL AP for STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE)